Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
BofAS Raises AKESO (09926.HK) TP to HKD164, Reiterates Buy Rating
Recommend 13 Positive 16 Negative 9 |
||||
|
||||
|
BofAS issued a report stating that AKESO (09926.HK) presented the overall survival analysis of the HARMONi-6 study at the oral Plenary Session of ASCO 2026. This marks the first time in ASCOs 61-year history that an innovative oncology drug originally developed in China has been selected for the Plenary Session. Given the strong HARMONi-6 data, the broker raised the probability of success for the China 1L sqNSCLC indication from 90% to 95%, and increased the probability of success for the global market from 60% to 65%. It also lifted its assumption for ivonescimabs potential market share in China. After incorporating these adjustments, the broker increased its revenue forecasts for AKESO for 2026-2028 by 1.7%/1.5%/1.1%, and raised its net profit forecasts by 10.9%/2.8%/3.6%, respectively. The TP was lifted from HKD162.8 to HKD164, with the Buy rating reiterated. The positive view is supported by robust clinical data and multiple upcoming pipeline catalysts. (ha/u) Auto-translated by AI This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. More Details
AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
